Skip to content
Review Open access

Patient-Reported Outcomes Following Initiation or Simplification of Treatment With iGlarLixi in Adults With Type 2 Diabetes: A Narrative Review.

Oct 2026 · Diabetes, obesity and metabolism · 0 citations · 49 references
Medicine

TL;DR

In conclusion, a once-daily injection of iGlarLixi may offer a clinically beneficial, simplified treatment option for adults with T2D compared with complex insulin-based regimens.

Abstract

INTRODUCTION Given the significant burden that diabetes self-management poses, it is important to assess patient-reported outcomes (PROs) for Type 2 diabetes (T2D) treatments in clinical trials and real-world studies. Complex insulin regimens are associated with increased risk of hypoglycaemia and body weight gain, which could negatively impact treatment adherence and, therefore, achievement of glycaemic targets. iGlarLixi is a once-daily fixed-ratio combination of insulin glargine 100 U/mL and the glucagon-like peptide-1 receptor agonist (GLP-1 RA), lixisenatide. iGlarLixi is an effective treatment alternative to complex insulin regimens, with a favourable between-group difference in body weight and reduced risk of hypoglycaemia.

Methods

This is the first review to summarise data from multiple validated PRO measures for recent iGlarLixi studies (Soli-CGM, SoliMix, Soli-SWITCH, IDEAL, SUCCESS and SIMPLIFY JP), including: Global Treatment Effectiveness Evaluation, Audit of Diabetes Dependent Quality of Life, Diabetes Medication Satisfaction Tool, Diabetes Therapy-Related Quality of Life, Diabetes Treatment Satisfaction Questionnaire, Hypoglycaemic Attitudes and Behaviour Scale and Treatment-Related Impact Measure Diabetes.

Results

In clinical studies, once-daily iGlarLixi was associated with numerical improvements in selected treatment satisfaction measures in those who switched from: complex insulin regimens (once- or twice-daily premixed insulin and basal-bolus insulin), basal insulin or oral glucose-lowering medications. Additionally, in real-world studies, iGlarLixi was generally associated with improvements in treatment satisfaction and quality of life outcomes in adults with T2D who previously received basal-bolus insulin or oral glucose-lowering medications ± basal insulin or GLP-1 RAs.

Conclusions

In conclusion, a once-daily injection of iGlarLixi may offer a clinically beneficial, simplified treatment option for adults with T2D compared with complex insulin-based regimens.

Read PDF

Similar papers

Open access Oct 2026

RETROSPECTIVE STUDY OF EFFICACY AND SAFETY OF THE COMBINATION LINAGLIPTIN, EMPAGLIFLOZIN, METFORMIN IN THE MANAGEMENT OF TYPE 2 DIABETES IN INDIA IN THE REAL-WORLD SETTING

Background: Type 2 diabetes mellitus (T2DM) is a progressive disorder with high cardiovascular (CV) risk, often inadequately controlled on monotherapy. This study aimed to evaluate real-world efficacy, safety, CV outcomes, tolerability and adherence of the empagliflozin, sitagliptin and metformin fixed-dose combination...

Nandkishor Shingne, Masiha Asar, Abdul Lateef Shaikh et al. · 0 citations
Review Open access Oct 2026

Safety and glycaemic outcomes of insulin-containing regimens in patients with type 2 diabetes mellitus during Ramadan: a systematic review and meta-analysis

In adults with type 2 diabetes mellitus, insulin-containing regimens during Ramadan were associated with a modest reduction in HbA 1c ; however, the clinical significance of this reduction remains uncertain.

H. Gad, T. Hayat, Z. Dabbous et al. · 0 citations
Open access Nov 2026

Efficacy and Safety of Dapagliflozin, Glimepiride, and Metformin Fixed-Dose Combination Tablet in Type 2 Diabetes: A Phase III Trial.

INTRODUCTION The global burden of type 2 diabetes mellitus (T2DM) is rapidly increasing, with India contributing significantly to the disease prevalence and associated economic burden. Despite metformin being the first-line therapy, many patients require combination treatment due to the progressive and multifactorial n...

Prakash Kurmi, M. Singh, Vishal Gupta et al. · 0 citations
Open access Oct 2026

Real-World Effectiveness, Documented Adverse Events, and Treatment Adherence of Semaglutide and Liraglutide in Omani Patients: A Retrospective Observational Study

Background: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are widely used in obesity and type 2 diabetes mellitus (T2DM), but comparative real-world evidence from the Middle East remains limited. We compared the effectiveness, documented adverse events, adherence and persistence of once-weekly semaglutide and o...

Najwa Al Himali, Hanan Al Habsi, Ahmed Al Mushrafi et al. · 0 citations
Open access Oct 2026

EFFECTIVENESS OF EMPAGLIFLOZIN AND LINAGLIPTIN AS ADD-ON THERAPY TO METFORMIN IN TYPE 2 DIABETES: PHYSICIAN INSIGHTS FROM SOUTHERN INDIA

Background: Type 2 diabetes mellitus (T2DM) is a chronic global health burden associated with cardiovascular (CV) and renal complications. This study aimed to evaluate real-world efficacy, cardiometabolic outcomes, and long-term outcomes of the empagliflozin + linagliptin add-on therapy to metformin in T2DM patients. M...

Nandkishor Shingne, Vrunda Patel, Swati Tiwari et al. · 0 citations
Open access Nov 2026

Reducing the Burden of Hypoglycemia in Type 1 Diabetes: The Impact of FLO23011 on Patient-Reported Outcomes and Glycemic Correlates of Treatment Response.

INTRODUCTION The aim of this study was to compare patient-reported outcomes (PROs) related to hypoglycemia recovery with FLO23011, a novel multi-energy substrate for hypoglycemia (MESH) recovery drink combining 15 g glucose with beta-hydroxybutyrate (BHB), versus standard glucose gel in adults with type 1 diabetes, and...

D. Russell-Jones, E. Meehan, V. Smout et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.